New
Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
BTEE ETF · iShares Nasdaq US Biotechnology UCITS ETF
The BTEE Exchange Traded Fund (ETF) is provided by iShares. It is built to track an index: NASDAQ Biotechnology Index. The BTEE ETF provides physical exposure, so by buying it you actually own parts of all the 262 underlying holdings. This share class generates a stream of income by distributing dividends.
Share class
Dist
USD
Last update 3/13/2026, 8:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.-3.64%
Last price
$8.27
1M perf.
-3.37%
1M flows
+€1.4M
AuM
€47M
E/R
0.35%
Rating
ESG Consensus®
BTEE
$8.27
Performance & flows
Segment for quartile rank
December 15, 2025 → March 13, 2026
Create a free account to view the flows graph
BTEE
$8.28
+0.16%
US Health Care
-3.10%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -3.37%  | +0.16% | +29.71%  | +44.72% | +17.97% | -5.35% | +0.21% | +0.21% | |
| Flows |
Key fund info
Segment for quartile rank
Main characteristics
More details
NAV
3/13/2026
$8.28
1D NAV change
-0.49%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
262
Inception date
3/5/2018
Jurisdiction
Ireland
Distribution
United Kingdom
Netherlands
Norway
France
Germany
Legal structure
Open-end Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Share class info
USD distributing
Total AuM of fund
€813M
Decimalisation of shares
No
Investment strategy
The iShares Nasdaq US Biotechnology UCITS ETF seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs
BTEC
1M perf.
-3.36%
E/R
0.35%
IBBQ
1M perf.
-3.33%
E/R
0.19%
203780
1M perf.
+1.98%
E/R
0.3%
00678
1M perf.
+0.59%
E/R
1.01%
IBB
1M perf.
-4.17%
E/R
0.44%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +0.16% | +29.71% | +44.72% | +17.97%  |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
93.74%
United Kingdom
1.47%
Ireland
1.30%
Bermuda
1.16%
Unavailable
0.11%
Other
2.22%
Sectors
Health Care
85.79%
Unavailable
14.19%
Diversification
Total weight of top 15 holdings out of 262
Top 15 holdings
Data as of January 31, 2026
GILEAD SCIENCES
VERTEX PHARMACEUTICALS
AMGEN-T
REGENERON PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
INSMED
BIOGEN INC
US04016X1019
Create a free account to view top holdings
ILLUMINA
UTD THERAPEUT
INCYTE
REVOLUTION MEDICINES INC
MODERNA INC
ROYALTY PHARMA
MEDPACE HOLDINGS INC
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
ESG Consensus® by Conser
Data as of December 31, 2025
MethodologyOur partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about BTEE ETF's sustainability, based on their methodology.
ESG Consensus®
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
BTEE’s has a Final Sustainability Grade of either B+, B, or B-.
A+
A
A-
B+
B
B-
C+
C
C-
D
This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight EnterpriseHoldings review
89.68% of holdings have positive scoring
10.43% of holdings have negative scoring
5.63%
62.70%
21.35%
6.10%
Consensus levels
Strong
Medium
Weak
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
NASDAQ Biotechnology Net Total Return Index - USD
Index ticker
XNBINNR Index
Index dividend policy
NTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
iShares
iShares ID Card
Number of funds
1720
Total AuM
€4.9T
Expense ratio range
0.03% - 1.51%
Average expense ratio
0.285%
Top 5 funds by iShares
| AuM | ||
|---|---|---|
IVV | iShares Core S&P 500 ETF | €604.11B |
IEFA | iShares Core MSCI EAFE ETF | €145.9B |
AGG | iShares Core U.S. Aggregate Bond ETF | €120.51B |
IEMG | iShares Core MSCI Emerging Markets ETF | €118.19B |
CSSPX | iShares Core S&P 500 UCITS ETF | €112.42B |
Frequently asked questions about BTEE
What does iShares Nasdaq US Biotechnology UCITS ETF, BTEE, invest in?
BTEE is a Passive ETF. This ETF provides exposure to US Equities.
Which benchmark or index does BTEE replicate?
BTEE tracks the NASDAQ Biotechnology Net Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of BTEE?
BTEE carries a total expense ratio (TER) of 0.35%, indicating the annual cost for holding the fund.
When was BTEE launched?
BTEE was introduced to the market on March 5, 2018. It trades on United Kingdom, among other exchanges
Who is the ETF issuer of BTEE?
iShares Nasdaq US Biotechnology UCITS ETF, BTEE, is provided by iShares. Learn more about iShares here.
Does BTEE have multiple share classes?
Yes, BTEE is available in multiple share classes, which may differ by distribution policy (e.g., accumulating vs. distributing), currency or hedging. Explore the different share classes .
What is the current assets under management (AUM) of BTEE?
BTEE oversees €47M in assets as of March 13, 2026.
How has BTEE performed lately?
Based on data from March 13, 2026, BTEE returned -3.37% over the past month, 0.16% over the last three months and 0.21% year-to-date.
What are the latest inflows or outflows for BTEE?
As of March 13, 2026, BTEE recorded net flows of +€1.3M over the last month and +€2.3M year-to-date.
Does BTEE distribute dividends?
BTEE follows a distributing dividend policy, meaning it pays out income to investors. As of March 13, 2026, its 12-month trailing yield was 0.37%.
What are the main country or region exposures of BTEE?
As of January 31, 2026, BTEE has significant geographic allocations in USA, United Kingdom and Ireland.
In which sector or theme does BTEE invest in?
As of January 31, 2026, BTEE focuses largely on Health Care.
How many securities does BTEE hold and how diversified is it?
As of January 31, 2026, BTEE holds 262 positions in its portfolio, with 52.04% of assets concentrated in its top 15 holdings.
What are the main positions in BTEE?
As of January 31, 2026, BTEE top three holdings include GILEAD SCIENCES, VERTEX PHARMACEUTICALS and AMGEN-T.
What is the base currency of BTEE?
The base currency of BTEE is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
